Dynamic Capital Management LTD Cut Deere & Co (DE) Position By $8.14 Million; Recro Pharma, Inc. (REPH) Had 9 Bullish Analysts

February 23, 2018 - By Marie Mckinney

Dynamic Capital Management Ltd decreased Deere & Co (DE) stake by 88.77% reported in 2017Q3 SEC filing. Dynamic Capital Management Ltd sold 65,104 shares as Deere & Co (DE)’s stock rose 9.64%. The Dynamic Capital Management Ltd holds 8,232 shares with $1.03M value, down from 73,336 last quarter. Deere & Co now has $53.46 billion valuation. The stock increased 0.74% or $1.21 during the last trading session, reaching $165.37. About 773,731 shares traded. Deere & Company (NYSE:DE) has risen 46.99% since February 23, 2017 and is uptrending. It has outperformed by 30.29% the S&P500.

Among 9 analysts covering Recro Pharma (NASDAQ:REPH), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 15 analyst reports since August 25, 2015 according to SRatingsIntel. On Thursday, July 20 the stock rating was maintained by Roth Capital with “Buy”. Roth Capital maintained Recro Pharma, Inc. (NASDAQ:REPH) on Thursday, November 9 with “Buy” rating. Roth Capital initiated the shares of REPH in report on Friday, September 16 with “Buy” rating. Aegis Capital initiated the stock with “Buy” rating in Monday, November 14 report. The firm has “Hold” rating given on Tuesday, August 25 by Zacks. The firm has “Buy” rating given on Friday, September 16 by TH Capital. The rating was initiated by H.C. Wainwright on Tuesday, November 24 with “Buy”. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Monday, July 31 by Roth Capital. The rating was initiated by Janney Capital with “Buy” on Monday, August 29. The firm earned “Overweight” rating on Monday, December 19 by Piper Jaffray. See Recro Pharma, Inc. (NASDAQ:REPH) latest ratings:

13/02/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Initiate
09/11/2017 Broker: Roth Capital Rating: Buy New Target: $18.0 Maintain

Analysts await Deere & Company (NYSE:DE) to report earnings on May, 18. They expect $2.87 earnings per share, up 15.26% or $0.38 from last year’s $2.49 per share. DE’s profit will be $927.75 million for 14.41 P/E if the $2.87 EPS becomes a reality. After $1.31 actual earnings per share reported by Deere & Company for the previous quarter, Wall Street now forecasts 119.08% EPS growth.

Since September 18, 2017, it had 0 buys, and 11 selling transactions for $29.11 million activity. Shares for $954,021 were sold by Guinn Max A on Friday, October 27. May John C II also sold $2.81 million worth of Deere & Company (NYSE:DE) on Monday, October 2. Another trade for 22,095 shares valued at $3.76 million was made by Field James M. on Friday, January 12. Shares for $3.46 million were sold by Jones Mary K.W.. Another trade for 6,416 shares valued at $972,253 was sold by Reed Cory J. von Pentz Markwart sold $2.65M worth of stock or 22,095 shares. 32,183 shares were sold by Gilles Jean H, worth $5.34M.

Dynamic Capital Management Ltd increased Marriott Intl Inc New (NASDAQ:MAR) stake by 4,577 shares to 12,195 valued at $1.35M in 2017Q3. It also upped Rite Aid Corp (NYSE:RAD) stake by 534,030 shares and now owns 918,684 shares. Apple Inc (NASDAQ:AAPL) was raised too.

Investors sentiment decreased to 0.93 in Q3 2017. Its down 0.07, from 1 in 2017Q2. It is negative, as 64 investors sold DE shares while 312 reduced holdings. 69 funds opened positions while 281 raised stakes. 213.38 million shares or 1.82% more from 209.56 million shares in 2017Q2 were reported. Carroll Financial Assoc Inc holds 1,803 shares or 0.03% of its portfolio. Robecosam Ag holds 0.4% of its portfolio in Deere & Company (NYSE:DE) for 41,543 shares. Scotia Cap reported 31,212 shares stake. Brown Brothers Harriman reported 149,501 shares. 2,990 are owned by Meiji Yasuda Life Insurance. Teachers Retirement Of The State Of Kentucky has 0.05% invested in Deere & Company (NYSE:DE) for 32,500 shares. Gulf Comml Bank (Uk) reported 0.15% of its portfolio in Deere & Company (NYSE:DE). Miller Management LP stated it has 7,440 shares or 0.3% of all its holdings. Piedmont Investment Advsr Ltd Co holds 104,398 shares or 0.28% of its portfolio. Tide Point Lp owns 369,316 shares. 7,720 were accumulated by Chicago Equity Prtn Limited Liability Company. Generation Inv Mgmt Ltd Liability Partnership holds 3.13M shares. Acadian Asset Mngmt Limited Liability reported 1,274 shares. Sarl holds 0.99% or 94,600 shares in its portfolio. 2,407 were accumulated by Bank Of Nova Scotia Com.

Among 29 analysts covering Deere & Company (NYSE:DE), 13 have Buy rating, 3 Sell and 13 Hold. Therefore 45% are positive. Deere & Company had 123 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Deere & Company (NYSE:DE) has “Hold” rating given on Wednesday, September 7 by Deutsche Bank. As per Tuesday, February 20, the company rating was maintained by Credit Suisse. The stock of Deere & Company (NYSE:DE) earned “Neutral” rating by PiperJaffray on Monday, November 28. UBS maintained it with “Neutral” rating and $87 target in Monday, August 22 report. UBS maintained the stock with “Neutral” rating in Tuesday, February 20 report. The stock of Deere & Company (NYSE:DE) earned “Buy” rating by Goldman Sachs on Friday, June 3. On Friday, August 18 the stock rating was downgraded by Robert W. Baird to “Neutral”. As per Friday, November 25, the company rating was maintained by RBC Capital Markets. As per Monday, August 21, the company rating was maintained by RBC Capital Markets. The stock of Deere & Company (NYSE:DE) has “Sell” rating given on Wednesday, August 19 by William Blair.

Since December 12, 2017, it had 0 buys, and 5 sales for $1.43 million activity. On Tuesday, January 2 SCP Vitalife Partners (Israel) II – L.P. sold $115,139 worth of Recro Pharma, Inc. (NASDAQ:REPH) or 12,964 shares. SCP Vitalife Partners II LP sold 4,732 shares worth $41,822. Broadfin Healthcare Master Fund Ltd had sold 93,237 shares worth $919,128 on Tuesday, December 12.

Investors sentiment decreased to 1.65 in 2017 Q3. Its down 0.56, from 2.21 in 2017Q2. It turned negative, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported. Alyeska Invest Grp Incorporated Lp reported 906,398 shares stake. Wells Fargo Mn holds 24,508 shares or 0% of its portfolio. Jacobs Levy Equity Management Inc owns 33,164 shares. Cadence Mgmt Ltd Liability Corp invested in 167,637 shares or 0.09% of the stock. Blackrock Inc stated it has 998,056 shares or 0% of all its holdings. Granite Point Cap Management Limited Partnership holds 38,000 shares or 0.07% of its portfolio. Vanguard stated it has 666,252 shares. Morgan Stanley has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). New York State Common Retirement Fund owns 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 1,800 shares. Deutsche Bank Ag invested in 0% or 12,601 shares. 25,231 are owned by Opus Point Management Ltd Liability. Royal Savings Bank Of Canada reported 1,308 shares. Rhumbline Advisers reported 15,411 shares. State Bank Of America Corp De invested 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Savings Bank Of Montreal Can invested in 4,328 shares.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $164.30 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>